Search

Displaying results 4621 - 4630 of 7687 in total
  1. Drug

    Cipepofol

    go.drugbank.com/drugs/DB16295
    ApprovedInvestigational

    [L63931] Cipepofol is approved in the United States for induction of general anesthesia in adults undergoing surgery, an approval Haisco announced on June 1, 2026. … Cipepofol is an intravenous general anesthetic of the alkylphenol class, supplied as a sterile lipid emulsion, which is thought to act by positively modulating the inhibitory function of GABA at ligand-gated

  2. Drug

    Nesvategrast

    go.drugbank.com/drugs/DB19337
    Investigational

    Nesvategrast is under investigation in clinical trial NCT05409235 (Nesvategrast (OTT166) in Diabetic Retinopathy (DR)).

  3. Drug

    Argan oil

    go.drugbank.com/drugs/DB14310
    Investigational

    It is not an approved drug.

  4. Drug

    Macadamia oil

    go.drugbank.com/drugs/DB14330
    Investigational

    It is not an approved drug.

  5. Drug

    QR-313

    go.drugbank.com/drugs/DB17867
    Investigational

    QR-313 is an antisense oligonucleotide targeting exon 73. It is being investigated for the treatment of dystrophic epidermolysis bullosa.[A259867]

  6. Drug

    LV305

    go.drugbank.com/drugs/DB17288
    Investigational

    LV305 is an active component of CMB305 along with [G305].[L47346]

  7. Drug

    Phenindamine

    go.drugbank.com/drugs/DB01619
    Approved

    Phenindamine is an antihistamine. Phenindamine blocks the effects of the naturally occurring chemical histamine in your body.

  8. Drug

    LP-2307

    go.drugbank.com/drugs/DB17470
    Experimental

    LP-2307 is an investigational allogeneic large multivalent immunogen (LMI) vaccine developed by Avanir. It was investigated for melanoma.

  9. Drug

    SMART101

    go.drugbank.com/drugs/DB18370
    Investigational

    SMART101 is an investigational cell therapy comprising human allogeneic CD34-CD7+ T cell progenitors that were cultured ex vivo.

  10. Drug

    ALLO-605

    go.drugbank.com/drugs/DB18641
    Investigational

    ALLO-605 is an allogeneic turbo chimeric antigen receptor (Turbocar) T Cell therapy targeting B Cell maturation antigen (BCMA).